Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Core Insights - Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on developing MasterKey therapies targeting oncogenic mutations in cancer patients [1][3] - The company will present results from its Phase 2 clinical trial of silevertinib and provide a program update on December 3, 2025 [1] Company Overview - Black Diamond Therapeutics specializes in MasterKey therapies designed to address a wide range of genetically defined tumors, overcome resistance, and minimize toxicities associated with wild-type [3] - The company is advancing a Phase 2 trial for silevertinib, a fourth-generation EGFR MasterKey inhibitor, specifically targeting EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma [3]